热门资讯> 正文
Medirom将收购日本基因医学的多数股权
2024-07-11 04:34
- Medirom Healthcare Technologies (NASDAQ:MRM) on Wednesday said that it plans to acquire a 70% majority stake in Japan Gene Medicine.
- The company added that it had entered into a share transfer agreement on June 30, 2024.
- The total transfer consideration would amount to 2B yen, in which 350 shares of common stock of Japan Gene Medicine would be transferred.
- The company had also entered into a legally binding memorandum of understanding, to obtain an option to acquire the remaining 30% of Japan Gene Medicine.
- The company expects to finance the transaction using its own funds and borrowings.
- Press release.
More on MEDIROM Healthcare Technologies - ADS
- Financial information for MEDIROM Healthcare Technologies - ADS
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
